Our assurance during the COVID-19 pandemic

During the COVID-19 pandemic, our commitment to patients, our employees and the communities where we operate remains unchanged. We will continue to supply our medicines to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.

 


COVID-19 and medicine supply

COVID-19 and medicine supply

During the COVID-19 pandemic, our key priority is to safeguard the health of our employees and the continued supply of our lifesaving medicines to patients. Currently we are not experiencing any constraints with our production. 

We are aware that health authorities and pharmacies are doing their best to ensure the availability of insulin for those who need it during the coronavirus pandemic, and we can assure you that our current stock levels are normal. It is important for us that you are informed and reassured. As we continue to monitor the situation, we will share our updates.

If you have any questions or concerns, please contact Novo Nordisk Canada Customer Care at 1-800-465-4334. 

COVID-19 and medicine supply

People living with diabetes and other serious chronic disease

If you, or someone you know, is living with diabetes, obesity, or another serious chronic disease, there is no doubt you have some concerns. As many of us are being asked to stay home, there are many questions about both physical and mental concerns.

For support and information, we encourage you to visit Diabetes Canada, Obesity Canada and JDRF for more information.

 

 

 

COVID-19 and medicine supply

Taking care of our employees

To protect the health and safety of our employees, we have asked Canadian employees to work from home effective March 16.

During these extraordinary working conditions, we are ensuring employees have support to keep active, work ergonomically from home and adopt to a digital workplace.

Our medicines sold in Canada are produced at various manufacturing facilities around the globe, including in Denmark, the United States, Brazil and France. At our production sites, we are taking measures to keep the number of employees working as low as possible and to practice recommended social distancing practices when on the job. We are asking only those employees for whom COVID-19 is not considered a health risk to work.